Oral Ketamine for Treatment-Resistant Depression: Does It Work?

Treatment-resistant depression (TRD) is a formidable mental health challenge that affects millions of people worldwide. For individuals who have not responded to conventional antidepressant medications and psychotherapy, the search for effective treatments can be arduous and disheartening. In recent years, there has been growing interest in the potential of oral ketamine as a novel and promising option for managing TRD. This article covers the efficacy of oral ketamine for TRD, shedding light on its potential benefits, risks, and current research findings, with related implications for the substantial subset of patients dealing with chronic pain and depression at the same time.

New to TRD? For background on the diagnosis itself, see understanding treatment-resistant depression.

Understanding TRD

TRD, also known as refractory depression, is a condition where individuals continue to experience depressive symptoms despite trying multiple standard antidepressant therapies. These conventional treatments, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT), are effective for many individuals with depression, but they do not work for everyone. About 30 to 40 percent of patients with major depression do not achieve remission after multiple medication trials. The landmark STAR*D study found that by the fourth medication attempt, remission rates dropped to roughly 13 percent. TRD's resistance to these traditional treatment approaches makes it a complex and often debilitating condition.

A Quick Note on What "Oral Ketamine" Actually Means

When patients (and most internet content) say "oral ketamine," they almost always mean sublingual ketamine: a troche, oral dissolving tablet (ODT), or rapidly dissolving tablet (RDT) that you hold under the tongue or in the cheek pocket, not a pill you swallow. That's the format used by virtually every at-home ketamine program, including ours, and it's what the rest of this article is about. Pure swallowed-oral ketamine (a pill that goes straight to the stomach) exists as a backup option but is much less common in practice; we'll touch on it briefly later.

The Emergence of Ketamine

Ketamine is a dissociative anesthetic that has been used for decades in medical and veterinary settings. In recent years, it has gained attention as a potential breakthrough in the treatment of TRD. Intravenous (IV) ketamine has been used successfully in clinical settings as a rapid-acting antidepressant; the foundational NIMH trial (Zarate 2006) showed 71% of patients responded at 24 hours after a single sub-anesthetic infusion. IV requires clinic-level medical supervision, which is not accessible to everyone.

Sublingual Ketamine as the Standard At-Home Alternative

Sublingual ketamine (held under the tongue as a troche or ODT) is the standard at-home alternative to IV. It can be taken at home, removing the need for frequent clinic visits or IV infusions. The published evidence has grown substantially in 2023 to 2026, and the picture is more nuanced than the early enthusiasm suggested.

Rapid Onset of Action

Like IV ketamine, sublingual ketamine produces rapid antidepressant effects relative to standard antidepressants. Most patients notice initial reductions in depressive symptoms within 24 to 72 hours of the first session, compared with the four to eight weeks SSRIs typically require. This quick onset is especially valuable for individuals in crisis or those who have cycled through multiple failed antidepressants.

Bioavailability and Dosing

The lower bioavailability vs IV (sublingual lands at 25-32%; swallowed-oral lands at just 16-29%, mostly around 17%) is compensated for by upward dose titration. The active metabolite norketamine accumulates more with sublingual and swallowed dosing than with IV; some pharmacokinetic analyses estimate the combined ketamine + norketamine effective bioavailability of oral routes reaches about 59% when norketamine is counted. The hepatic first-pass step (CYP3A4 and CYP2B6) is what drops the parent-drug number; norketamine is itself pharmacologically active and contributes to clinical effect.

Response Rates

Real-world response rates for sublingual at-home ketamine in TRD populations cluster around 60 to 70 percent, comparable to the 65 to 75 percent typically reported for IV protocols (the small gap is likely within population variance). The Murrough 2013 two-site IV trial showed 64% response at 24 hours; the Alnefeesi 2022 real-world meta-analysis (79 studies, 2,665 patients) confirmed substantial effectiveness across racemic ketamine and esketamine in real-world settings. For a medically stable at-home patient willing to engage with integration work, the sublingual route produces outcomes comparable to clinic-based IV at a fraction of the cost.

Improved Functioning

Studies tracking TRD patients on sublingual ketamine consistently report improvements in sleep architecture, ruminative-loop intensity, and emotional range, often before formal depression-rating scores fully normalize. Sleep is typically the earliest reliable signal, frequently appearing after the first session.

Lower Acute-Risk Profile

While all forms of ketamine carry some risk of side effects, sublingual administration produces slower onset and lower peak plasma levels than IV, which translates to a proportionally lower risk of acute adverse reactions. This makes the at-home route appropriate for medically stable patients who don't need clinic-level monitoring.

A Word on Swallowed-Oral as a Backup

For the small number of patients who genuinely can't tolerate the taste, texture, or oral numbness of sublingual troches, swallowed-oral ketamine (a pill or solution) is an option. Bioavailability drops to 16-29% (most studies cluster around 17%) and onset is slower at 30-45 minutes vs 10-20 minutes sublingual. Sublingual remains the default for everyone else.

Challenges and Considerations

Despite the promising aspects of oral ketamine for TRD, several challenges and considerations should be kept in mind:

Lack of Long-Term Data

The long-term safety and efficacy of oral ketamine are still being studied. More research is needed to understand its potential benefits and risks over extended periods.

Individual Variability

Responses to ketamine treatment can vary significantly among individuals. What works for one person may not work for another, making it important to tailor treatment plans to each patient's specific needs.

Safety Concerns

Ketamine is a controlled substance, and its misuse can lead to addiction and other serious health issues. Patients must be carefully screened and monitored during treatment to mitigate these risks.

Complementary Therapies

Ketamine treatment for TRD is often most effective when used in conjunction with other therapies, such as psychotherapy and lifestyle changes. A holistic approach to treatment is essential.

Conclusion

Sublingual ketamine (the route used by virtually all at-home programs, including ours) presents a real and increasingly well-evidenced option for the treatment of TRD, with response rates in the 60 to 70 percent range that approach what IV protocols achieve and substantially exceed the diminishing returns of additional standard antidepressant trials. The lower bioavailability versus IV is compensated for by upward dose titration and by the accumulation of the active metabolite norketamine. The route's main practical advantages are accessibility, cost, and the at-home setting itself, which many patients find more therapeutic than a clinic environment. As always, ketamine treatment should be pursued under physician supervision, with proper screening, and ideally in combination with integration work and existing psychiatric care.

Frequently Asked Questions

Does oral ketamine actually work for treatment-resistant depression?

Yes, with the terminology caveat above (most "oral ketamine" used in at-home programs is actually sublingual). Real-world response rates for sublingual at-home ketamine in TRD populations cluster around 60 to 70 percent, comparable to IV. The caveats: response is more variable than with IV due to bioavailability differences, integration work matters more for durable response, and "response" (50% symptom reduction) doesn't always equal full remission. For patients who have failed two or more conventional antidepressants, the case for trying sublingual ketamine is strong; for first-line depression, standard antidepressants remain appropriate.

How does sublingual at-home ketamine compare to IV for TRD?

Mechanistically the same; logistically and pharmacokinetically different. IV reaches ~100% bioavailability with onset in 2-5 minutes; sublingual lands at 25-32% bioavailability with onset in 10-20 minutes. Doses are titrated upward to compensate. Real-world TRD response rates: IV 65-75%, sublingual at-home 60-70%. The gap is small enough to be within population variance. The bigger difference is access: IV requires a clinic, while sublingual works at home. For medically stable patients without acute crisis, sublingual at-home produces comparable outcomes at a fraction of the cost.

Is "oral ketamine" the same as a pill you swallow?

In practice, no. When most people say "oral ketamine" they mean sublingual ODT/RDT/troche held under the tongue, not a swallowed pill. Sublingual reaches roughly 25-32% bioavailability with onset in 10-20 minutes; pure swallowed-oral lands at just 16-29% (cluster ~17%) with onset in 30-45 minutes due to extensive first-pass liver metabolism. Sublingual is the at-home standard; swallowed is a backup format for patients who can't tolerate the troche.

How many sessions of sublingual ketamine does TRD treatment require?

The standard induction is 10 or more sessions over 4 to 8 weeks. Most randomized trials show meaningful symptom reduction by session three to four with continued gains through the full series. After induction, patients typically move to spaced maintenance (every 4 to 8 weeks) for as long as they continue to benefit. Some respond robustly within the first six sessions and taper sooner; others with more severe or complex presentations need longer induction series.

Is sublingual ketamine FDA-approved for depression?

Not specifically. Spravato (esketamine nasal spray) is the one ketamine modality with FDA approval for treatment-resistant depression, administered in certified clinics under the REMS program. Sublingual racemic ketamine is prescribed off-label by physicians, which is legal and standard in clinical practice. Off-label does not mean unstudied or experimental; it means the specific FDA approval pathway hasn't been completed for the sublingual route in the depression indication.

Can I stay on my SSRI while taking sublingual ketamine?

Yes, in most cases. SSRIs and ketamine work through entirely different neurotransmitter systems (serotonin vs glutamate) and are generally complementary. Most patients continue their SSRI throughout ketamine treatment. Specific exceptions are MAOIs (require a 14-day washout) and high-dose tramadol (a hidden serotonergic agent). See our deep-dive on combining ketamine with SSRIs.

What about long-term safety of sublingual ketamine?

Better established than the original "we don't know" framing of a decade ago, but still less mature than for SSRIs. The main long-term considerations are bladder toxicity (rare at therapeutic doses, mostly seen with chronic recreational use of much higher doses), tolerance (some patients require dose adjustments over time), and the general principle that any prescription medication taken for years deserves periodic re-evaluation. The published 2026 evidence base is reassuring at standard therapeutic dosing under physician supervision.

Is sublingual ketamine right for me if I'm in acute crisis?

Probably not as the starting point. Acute suicidal ideation with plan or intent, severe psychotic features, or recent suicide attempts call for higher-acuity care: 988, an emergency department, or inpatient stabilization. Once acute risk is stabilized, at-home sublingual ketamine can be an excellent maintenance and prevention strategy. For acute TRD with severe but not crisis-level suicidal ideation, Spravato (in-clinic, FDA-approved with that specific indication) is generally the more appropriate choice.

How much does sublingual ketamine for TRD typically cost?

At Discreet Ketamine: $250 for a 1-month plan, $650 for 3 months, $1,200 for the most-common 6-month plan, $2,200 for a 1-year maintenance plan. HSA/FSA eligible. Insurance is generally not accepted for sublingual ketamine. Spravato (FDA-approved, in-clinic) is the one ketamine modality with reliable insurance coverage.

References

1. Dutton M, Can AT, Lagopoulos J, Hermens DF. Oral ketamine may offer a solution to the ketamine conundrum. Psychopharmacology (Berl). 2023;240(12):2483-2497. PubMed: 37882811 · Free full text Recent review establishing the oral-ketamine bioavailability range (16-29%, commonly ~17%) and the role of the active metabolite norketamine. Source for the "effective bioavailability ~59%" figure when norketamine is included.

2. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clin Pharmacokinet. 2016;55(9):1059-1077. PubMed: 27028535 Standard pharmacokinetics review across routes of administration. Source for first-pass metabolism via CYP3A4/CYP2B6 and bioavailability comparisons across IV/IM/sublingual/oral.

3. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. PubMed: 16894061 Foundational NIMH trial: 71% response at 24 hours after single sub-anesthetic IV ketamine in TRD. The mechanistic and clinical baseline for everything that has come since.

4. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142. PubMed: 23982301 Two-site IV ketamine RCT showing 64% response at 24 hours vs 28% with midazolam. The basis for the "65-75% IV response rate" benchmark referenced in the body.

5. Alnefeesi Y, Chen-Li D, Krane E, et al. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review and meta-analysis. J Psychiatr Res. 2022;151:693-709. PubMed: 35688035 Meta-analysis of 79 real-world studies (2,665 patients) confirming effectiveness across both racemic ketamine and esketamine. The basis for real-world response-rate claims.

6. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. PubMed: 17074942 The STARD study referenced in the body for the diminishing-returns pattern across antidepressant trials and the "30-40% non-responder" figure.*

---

Ready to Start Your Healing Journey?

If you're interested in exploring whether ketamine therapy might be right for you, I'm here to help. Dr. Ben Soffer is a board-certified physician providing personalized, discreet at-home ketamine treatment for depression, anxiety, PTSD, and chronic pain.

Check Your Eligibility →

Discreet Ketamine provides at-home ketamine therapy to residents of Florida and New Jersey. All treatments are supervised by Dr. Ben Soffer, a board-certified physician.